SPY412.17-3.04 -0.73%
DIA338.12-2.63 -0.77%
IXIC13,786.27-128.50 -0.92%

Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Raises Price Target to $60

Morgan Stanley analyst Jeffrey Hung maintains Prelude Therapeutics (NASDAQ:PRLD) with a Equal-Weight and raises the price target from $47 to $60.

· 03/17/2021 07:39
Morgan Stanley analyst Jeffrey Hung maintains Prelude Therapeutics (NASDAQ:PRLD) with a Equal-Weight and raises the price target from $47 to $60.